Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 253-775-4 | CAS number: 38083-17-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2007-01-03 to 2007-02-02
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was performed according to OECD guideline No. 474 and followed the principles of GLP.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: ICH S2A (1996)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: ICH S2B (1997)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: SCCNFP Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation (2004)
- Deviations:
- no
- Principles of method if other than guideline:
- not applicable
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
Test material
- Reference substance name:
- Climbazole
- EC Number:
- 253-775-4
- EC Name:
- Climbazole
- Cas Number:
- 38083-17-9
- Molecular formula:
- C15H17ClN2O2
- IUPAC Name:
- 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- ICR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan (Frederick, MD, USA)
- Age at study initiation: 7 to 9 weeks
- Weight at study initiation:
Toxicity study: males: 25.1-30.0 g
females: 25.6-29.6 g
Supplemetal toxicity study: males: 25.7-30.5 g
females: 23.1-27.6 g
Micronucleus test: males: 34.8-38.3 g
- Assigned to test groups randomly: yes, based on equalization of mean group body weight
- Housing: up to 5 mice of the same sex were housed together in rodent Micro-Barrier cages in an AAALAC-accredited facilty. Heat-treated hardwood chips were used for bedding.
- Diet: certified laboratory rodent chow (Harlan 2018C Certified Global Rodent Diet), ad libitum
- Water: tap water, ad libitum
- Air change: constantly
- Acclimation period: not less than 5 d
ENVIRONMENTAL CONDITIONS
- Temperature: 72±3°F (22.2±1.7°C)
- Humidity: 50±20%
- Photoperiod: 12 h dark / 12 h light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle used: polyethylene glycol 200 (PEG 200)
- Justification for choice of vehicle: request of the study sponsor
- Concentration of test material in vehicle: 3.75, 5, 7.5, 01, 15, 20, 30, 40, 50, and 100 mg/mL
- Amount of vehicle: 10 mL/kg body weight - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Dosing solutions were prepared freshly just prior to administration as follows:
An appropriate amount of test article for each concentration (3.75, 5, 7.5, 10, 15, 20, 30, 40, 50 and 100 mg/mL) was weighed and combined with an appropriate amount of vehicle and the mixture was vortexed and stirred using a magnetic stir plate/stir bar for ~45 min until a clear, coluorless solution was formed.
Samples of the dose formulations at concentrations of 0 mg/mL (vehicle) and at 3.75, 7.5, and 15 mg/mL were subjected to chemical analysis.
The overall results of these analyses indicate the accuracy of preparation and stability of the formulations used in this study. - Duration of treatment / exposure:
- Initial and supplemental toxicity study: Obervation for 3 d after dosing
Micronucleus test: sacrifice at 24 h (all low-dose, medium-dose and positive control animals as well as 5 animals each of the vehicle control and the high-dose group) or 48 h after dosing (the remaining animals of the vehicle control and the high-dose group) - Frequency of treatment:
- once (single dose)
- Post exposure period:
- not applicable
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
Initial toxicity study: 50, 100, 300, 400, 500, and 1000 mg/kg
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
Supplemental toxicity study: 100, 150, and 200 mg/kg
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
Micronucleus test: 37.5, 75, and 150 mg/kg
Basis:
actual ingested
- No. of animals per sex per dose:
- Initial and supplemental toxicity study: 3 males and 3 females per group
Micronucleus test: 5 males each at the low and the medium dose level and for the positive control, 10 males for the vehicle control, 15 males at the high dose level
(since no differences in the toxicity between male and female mice were observed in the two dose range finding studies, only males were used in the definitive micronucleus test) - Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Cyclophosphamide monohydrate (CP, CAS number 6055-19-2), obained from Sigma-Aldrich, dissolved in sterile distilled water (5 mg/mL)
- Route of administration: oral, by gavage
- Dose: 50 mg/kg
Examinations
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
Dose levels for the definite micronucleus test were defined based on the results obtained from the intial and the supplemental toxicity study.
DETAILS OF SLIDE PREPARATION:
At the scheduled bone marrow collection time, five mice per sex per treatment were euthanized by CO2 asphyxiation. Immediately following euthanasia, the femurs were exposed, cut just above the knee, and the bone marrow was aspirated into a syringe containing fetal bovine serum. The bone marrow cells were transferred to a labelled centrifuge tube containing approximately 1 mL foetal bovine serum. The bone marrow cells were pelleted by centrifugation at approximately 100 x g for 5 min and the supernatant was drawn off, leaving a small amount of serum with the remaining cell pellet. The cells were resuspended by aspiration with a capillary pipette and a small drop of bone marrow suspension was spread onto a clean glass slide. Two slides were prepared from each mouse. The slides were fixed in methanol, stained with May-Gruenwald-Giemsa and permanently mounted.
METHOD OF ANALYSIS:
Slides were scored using a light microscope and a medium magnification (400X), an area of acceptable quality was selected such that the cells were well spread and stained. Using oil immersion (1000X), the numbers of polychromatic erythrocytes (PCEs) normochromatic erythrocytes (NCEs) and micronuclei were determined.
Two-thousand PCEs per mouse were scored for the presence of micronuclei, resulting in evaluation of a total of 10000 PCEs per each treatment group. The number of NCEs and micronucleated NCEs (MNCEs) in the field of 1000 total erythrocytes (ECs) is determined for each animal to determine the proportion of polychromatic erythrocytes to total erythrocytes (PCEs/ECs). The incidence of MNCEs per 2000 PCEs was enumerated for each animal, but the result was not given in the report. The proportion of polychromatic erythrocytes to total erythrocytes was also recorded per 1000 erythrocytes per each animal (PCEs/ECs ratio). - Statistics:
- The incidence of MNPCEs per 2000 PCEs was determined for each mouse and treatment group.
Statistical significance was determined using one way analysis of variance and Dunnett’s t-test (post hoc) for group mean comparison and regression analysis for detecting any trend using square-root transformed data (square root of MNPCEs/2000 PCEs + 1) using a “p” value of ≤ 0.05.
All analyses were performed separately for each sampling time.
To quantify the test articles effect on erythropoiesis, the proportion of PCEs to total erythrocytes was determined for each animal and treatment group (PCEs/total erythrocyte ratio).
Results and discussion
Test results
- Sex:
- male
- Genotoxicity:
- negative
- Remarks:
- no significant increase in the frequency of micronucleus formation was observed in any of the treated groups
- Toxicity:
- yes
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF THE INITIAL ANS SUPPLEMENTAL TOXICITY STUDIES
- Dose range: initial toxicity study: 50-1000 mg/kg; supplemental toxicity study: 100-200 mg/kg
- Solubility: The test article formed a clear, colourless solution in the vehicle at concentrations of up to 100 mg/mL, the maximum concentration tested in this study.
- Clinical signs of toxicity in test animals:
Mortality was observed in 1/3 males at 150 mg/kg, 1/3 males at 200 mg/kg, 2/3 females at 300
mg/kg, 1/3 males and 1/3 females at 400 mg/kg, 1/3 males and 2/3 females at 500 mg/kg, and 3/3
males and 1/3 females at 1000 mg/kg. Clinical signs of toxicity (e.g., hyperactivity, prostration, irregular breathing, and excessive salivation) were observed at all concentrations of the test article, increasing in severity with dose. Reductions in mean (group) body weights, up to 19.5%, were observed in some of the test article treated groups.
- Rationale for exposure: Determination of appropriate dose levles for the definite micronucleus test.
RESULTS OF DEFINITIVE MICRONUCLEUS TEST
- Induction of micronuclei: No significant increase in the incidence of MNPCEs was observed in any of the test article-treated groups relative to the respective vehicle control groups at 24 or 48 h after dose administration.
- Ratio of PCE/NCE: No appreciable reductions in the ratio of PCE to NCE were observed in the test article-treated groups relative to the respective vehicle control groups.
Signs of toxicity:
One male mouse (1/15) at 150 mg/kg was found dead at 24 h post dose. In addition to mortality, clinical signs of toxicity were observed in all test article treated groups, increasing in severity with dose (Tables 4 and 5). Reductions in mean (group) body weights up to ~ 10%, were observed in some of the test article treated groups.
Any other information on results incl. tables
Bone marrow micronucleus analysis
Treatment | Time (h) | Number of mice | PCE/total erythrocytes (mean) | PCE/total erythrocytes SD | Micronucleated PCE per 1000 (mean) | Micronucleated PCE per 1000 SD | Significance |
PEG 200 | 24 | 5 M | 0.542 | 0.05 | 0.5 | 0.5 | - |
37.5 mg/kg Climbazole | 24 | 5 M | 0.570 | 0.05 | 0.2 | 0.27 | NS |
75 mg/kg Climbazole | 24 | 5 M | 0.497 | 0.05 | 0.2 | 0.27 | NS |
150 mg/kg Climbazole | 24 | 5 M | 0.507 | 0.06 | 0.4 | 0.42 | NS |
50 mg/kg Cyclophosphamide | 24 | 5 M | 0.590 | 0.02 | 17.0 | 3.55 | p<=0.05 |
PEG 200 | 48 | 5 M | 0.443 | 0.08 | 0.1 | 0.22 | - |
150 mg/kg Climbazole | 48 | 5 M | 0.421 | 0.05 | 0.4 | 0.22 | NS |
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): negative
In an in vivo micronucleus test in male ICR mice, animals received a single oral dose of the test item in polyethylene glycol 200 at dose levels of 37.5, 75, and 150 mg/kg. Upon bone marrow analysis after 24 and 48 hours, no significant increase in the incidence of polynucleated MNPCEs was observed and the test substance was judged to be negative in this assay. - Executive summary:
The genotoxic potential of crinipan (climbazole) was evaluated in an in vivo micronucleus test in male ICR mice. After a dose of 150 mg/kg habe been determined as the maximum tolerated dose in two preliminary toxicity studies in male and female ICR mice, groups of male ICR mice received a single oral administration of the test item in polyethylene glycol 200 at dose levels of 37.5, 75, and 150 mg/kg. Cyclophosphamide monohydrate (50 mg/kg) was used as positive control. At 24 or 48 h after adminstration, the animals were sacrificed, slides were prepared from their bone marrow cells, and the slides were scored for the occurence of micronuclei. The test item did not induce any significant increase in the frequency of micronucleus formation. Thus, crinipan (climbazole) was found to be negative under the conditions used in this assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.